EUVIMEDEUVIMED entdecken
Crossref

Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty

Simon Wolf, David Spirk, Gabor Forgo iD, Tim Sebastian iD, Davide Voci iD, Nils Kucher, Stefano Barco

Vasa · 2022-11 · 51 (6) · 357-364

DOI: 10.1024/0301-1526/a001025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vasa, 2022-11. Verfasst von Simon Wolf und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Angiology, University Hospital Zurich, Switzerland. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Peripheral Arterial Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: The global burden of peripheral arterial disease (PAD) is substantial. Reducing the major modifiable risk factors for noncommunicable disease, including dyslipidaemia, represents a public health priority. Aim is to evaluate the prevalent adequate use of lipid-lowering therapy (LLT) and low-density lipoprotein cholesterol (LDL-C) attainment among patients with PAD of the lower extremities undergoing percutaneous transluminal angioplasty. Patients and methods: We screened PAD patients treated at the University Hospital Zurich (January 2012–December 2018). We excluded patients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasPeripheral Arterial DiseaseMaleHumansAgedFemaleCholesterol, LDLCross-Sectional StudiesAngioplastyTreatment Outcome

Stichwörter der Autor:innen

DyslipidaemiaESC guidelineslipid-lowering therapyperipherial arterial diseasestatin

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Angiology, University Hospital Zurich, Switzerland.
  • Institute of Pharmacology, University of Bern, Switzerland.
  • Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Germany.

ORCID-Profile: Gabor Forgo, Tim Sebastian, Davide Voci

Zitieren

APA

Wolf, S., Spirk, D., Forgo, G., Sebastian, T., Voci, D., Kucher, N., & Barco, S. (2022). Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty. Vasa, 51(6), 357-364. https://doi.org/10.1024/0301-1526/a001025

Vancouver

Wolf S, Spirk D, Forgo G, Sebastian T, Voci D, Kucher N, et al. Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty. Vasa. 2022;51(6):357-364. doi:10.1024/0301-1526/a001025

BibTeX
@article{Wolf2022,
  author = {Wolf, Simon and Spirk, David and Forgo, Gabor and Sebastian, Tim and Voci, Davide and Kucher, Nils and Barco, Stefano},
  title = {Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty},
  journal = {Vasa},
  year = {2022},
  volume = {51},
  number = {6},
  pages = {357--364},
  doi = {10.1024/0301-1526/a001025}
}
Kostenlos starten →